Twist Bioscience (NASDAQ: [[ticker:TWST]]), a synthetic biology company that has developed a proprietary way of manufacturing DNA by “writing” it on a silicon chip, has promoted Patrick “Paddy” Finn to chief commercial officer, a newly created position. Previously Finn, who joined Twist in 2015, was senior vice president of commercial operations. Prior to Twist he held roles at companies including Enzymatics (now part of Quiagen (NYSE: [[ticker:QGEN]])), Agilent Technologies (NYSE: [[ticker:A]]), and Beckman Coulter.
Author: Sarah de Crescenzo
Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register.
She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine.
View all posts by Sarah de Crescenzo
